NASDAQ:PCSA

Processa Pharmaceuticals Stock Insider Trading

Healthcare > Biotechnology

Buy PCSA

*Your capital is at risk

$2.15

+0.110 (+5.39%)

At Close: Jul 31, 2026

Processa Pharmaceuticals Stock Insider Power

Based on the 100 latest insides trades, we have calculated the insider power to be positive at 100.00. In total, the insiders bought 6.23B and sold 0 PCSA shares in the last 100 trades. The insider score can be negative despite buy/sell ratio being positive. The score focuses on the quality of the trades.

Insider Power (Last 100 transactions)	100.00
● Buy	6.23B shares
● Sell	0 shares
100% Buy Activity Negligible or No Correlation
Buy Signal High Confidence Jul 16, 2026 Analysis Breakdown: Strongly supported by a very high Insider Power Score of 100. Confidence increased due to high data reliability score of 100. Supported by overwhelming buy-side pressure (100% buys).

Historical Insider Trades

Date	Type	Person	Role	Amount
Oct 01, 2025 Buy	Stock Options (Right to Buy) A-Award	Pannu Geraldine Director	Director	300 000 Value: $59.4K
Oct 01, 2025 Buy	Restricted Stock Units A-Award	Pannu Geraldine Director	Director	100 000 Value: $19.8K
Oct 01, 2025 Buy	Stock Options (Right to Buy) A-Award	Yorke Justin W Director	Director	300 000 Value: $59.4K
Oct 01, 2025 Buy	Restricted Stock Units A-Award	Yorke Justin W Director	Director	100 000 Value: $19.8K
Oct 01, 2025 Buy	Stock Options (Right to Buy) A-Award	Guy Wendy Chief Administrative Officer	Officer	150 000 Value: $29.7K
Oct 01, 2025 Buy	Restricted Stock Units A-Award	Guy Wendy Chief Administrative Officer	Officer	50 000 Value: $10K
Oct 01, 2025 Buy	Stock Options (Right to Buy) A-Award	Lin Patrick Chief Business - Strategy Off	Officer	204 000 Value: $40.4K
Oct 01, 2025 Buy	Restricted Stock Units A-Award	Lin Patrick Chief Business - Strategy Off	Officer	68 000 Value: $13.5K
Oct 01, 2025 Buy	Stock Options (Right to Buy) A-Award	Bigora Sian Chief Development Officer	Officer	288 000 Value: $57.0K
Oct 01, 2025 Buy	Restricted Stock Units A-Award	Bigora Sian Chief Development Officer	Officer	96 000 Value: $19.0K
Oct 01, 2025 Buy	Stock Options (Right to Buy) A-Award	Skibsted Russell Chief Financial Officer	C-Suite Officer	324 000 Value: $64.2K
Oct 01, 2025 Buy	Restricted Stock Units A-Award	Skibsted Russell Chief Financial Officer	C-Suite Officer	108 000 Value: $21.4K
Oct 01, 2025 Buy	Stock Options (Right to Buy) A-Award	Young David Pres. Research & Development	Officer	333 000 Value: $65.9K
Oct 01, 2025 Buy	Restricted Stock Units A-Award	Young David Pres. Research & Development	Officer	111 000 Value: $22.0K
Oct 01, 2025 Buy	Stock Options (Right to Buy) A-Award	Ng George K Chief Executive Officer	CEO / President	768 000 Value: $152.1K
Oct 01, 2025 Buy	Restricted Stock Units A-Award	Ng George K Chief Executive Officer	CEO / President	256 000 Value: $50.7K
Oct 01, 2025 Buy	Restricted Stock Units A-Award	Guy Wendy Chief Administrative Officer	Officer	50 000 Value: $10K
Oct 01, 2025 Buy	Stock Options (Right to Buy) A-Award	Guy Wendy Chief Administrative Officer	Officer	150 000 Value: $29.7K
Oct 01, 2025 Buy	Restricted Stock Units A-Award	Yorke Justin W Director	Director	100 000 Value: $19.8K
Oct 01, 2025 Buy	Stock Options (Right to Buy) A-Award	Yorke Justin W Director	Director	300 000 Value: $59.4K
Oct 01, 2025 Buy	Restricted Stock Units A-Award	Pannu Geraldine Director	Director	100 000 Value: $19.8K
Oct 01, 2025 Buy	Stock Options (Right to Buy) A-Award	Pannu Geraldine Director	Director	300 000 Value: $59.4K
Oct 01, 2025 Buy	Restricted Stock Units A-Award	Baluch Khoso Director	Director	100 000 Value: $19.8K
Oct 01, 2025 Buy	Stock Options (Right to Buy) A-Award	Baluch Khoso Director	Director	300 000 Value: $59.4K
Oct 01, 2025 Buy	Restricted Stock Units A-Award	Neal James R Director	Director	100 000 Value: $19.8K

About Insider Power

Insider Power is a proprietary algorithm developed by StockInvest.us to evaluate the significance of insider transactions. The calculation considers the size, type, and timing of transactions, as well as the insider’s role within the company.

It is important to note that, in general, there is little to no correlation between insider transactions and short-term stock price movements. In one of our studies, only 0.22%^* of stocks with insider activity showed a measurable correlation — and even then, it was unclear whether the effect was caused by insider actions or simply by the stock’s broader trend.

While our algorithms are designed to highlight potentially meaningful signals, these cannot be regarded as statistically significant on their own. Insider trading activity should therefore be seen as informative rather than as direct trading guidance. The Insider Power metric was created to present this information in a clearer and more accessible way, helping investors better understand the possible context of insider activity.

* October 6th, 2025 - Tested on 5562 stocks

ABOUT PROCESSA PHARMACEUTICALS INC.

Processa Pharmaceuticals, Inc., a clinical stage biopharmaceutical company, focuses on the development of drug products for the treatment of patients with unmet medical needs in the United States. Its lead product candidate is PCS499, an oral tablet that is in Phase 2B clinical trials for the treatment of ulcerative and non-ulcerative necrobiosis lipoidica, a chronic disfiguring condition. The company is also developing PCS12852, a novel selectiv...

Read Full Profile Here